Brief: Landos Biopharma Announces Transfer Of Lancl Portfolio, Including Omilancor, Labp-104 And Labp-111 To Landos’ Founder

Landos Biopharma

28/02/2023 22:08

Feb 28 (Reuters) - Landos Biopharma Inc  LABP.O :
    * LANDOS BIOPHARMA ANNOUNCES TRANSFER OF LANCL PORTFOLIO,
INCLUDING OMILANCOR, LABP-104 AND LABP-111 TO LANDOS’ FOUNDER
    * LANDOS BIOPHARMA INC - REMAINS ON-TRACK TO INITIATE NX-13
PHASE
2 PROOF-OF-CONCEPT TRIAL IN ULCERATIVE COLITIS IN Q2 OF 2023
    * LANDOS BIOPHARMA INC - TRANSACTION SOLIDIFIES COMPANY'S
NEAR-TERM STRATEGIC FOCUS ON ADVANCING CLINICAL DEVELOPMENT OF
NX-13
    * LANDOS BIOPHARMA - WILL REPURCHASE ABOUT 9.1 MILLION
SHARES
PREVIOUSLY HELD BY BASSAGANYA-RIERA, CERTAIN AFFILIATED
INDIVIDUALS, ENTITIES FOR $3.0 MILLION

Source text for Eikon:  ID:nGNX1j5CGr 
Further company coverage:  LABP.O 

 ((Reuters.Briefs@thomsonreuters.com;;))